These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24525428)

  • 1. Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.
    Al Nakouzi N; Cotteret S; Commo F; Gaudin C; Rajpar S; Dessen P; Vielh P; Fizazi K; Chauchereau A
    Oncotarget; 2014 Feb; 5(3):667-78. PubMed ID: 24525428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
    Li J; Wang R; Kong Y; Broman MM; Carlock C; Chen L; Li Z; Farah E; Ratliff TL; Liu X
    Mol Cancer Ther; 2017 Mar; 16(3):469-479. PubMed ID: 28069876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
    Hu K; Lee C; Qiu D; Fotovati A; Davies A; Abu-Ali S; Wai D; Lawlor ER; Triche TJ; Pallen CJ; Dunn SE
    Mol Cancer Ther; 2009 Nov; 8(11):3024-35. PubMed ID: 19887553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
    Reagan-Shaw S; Ahmad N
    FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
    Hu K; Law JH; Fotovati A; Dunn SE
    Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
    Lee HJ; Hwang HI; Jang YJ
    Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
    Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
    Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
    Li J; Karki A; Hodges KB; Ahmad N; Zoubeidi A; Strebhardt K; Ratliff TL; Konieczny SF; Liu X
    Mol Cell Biol; 2015 Dec; 35(24):4185-98. PubMed ID: 26438599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.
    Zhu Y; Liu C; Nadiminty N; Lou W; Tummala R; Evans CP; Gao AC
    Mol Cancer Ther; 2013 Sep; 12(9):1829-36. PubMed ID: 23861346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
    Feng B; Wang R; Chen LB
    Cancer Lett; 2012 Apr; 317(2):184-91. PubMed ID: 22120675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality.
    Xu Y; Wang Q; Xiao K; Liu Z; Zhao L; Song X; Hu X; Feng Z; Gao T; Zuo W; Zeng J; Wang N; Yu L
    Mol Cancer Ther; 2020 Jun; 19(6):1221-1231. PubMed ID: 32220972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
    Zhang Z; Hou X; Shao C; Li J; Cheng JX; Kuang S; Ahmad N; Ratliff T; Liu X
    Cancer Res; 2014 Nov; 74(22):6635-47. PubMed ID: 25252916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer.
    Sekino Y; Oue N; Shigematsu Y; Ishikawa A; Sakamoto N; Sentani K; Teishima J; Matsubara A; Yasui W
    Urol Oncol; 2017 Jan; 35(1):31.e13-31.e20. PubMed ID: 27665358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.
    Bagheri-Yarmand R; Nanos-Webb A; Biernacka A; Bui T; Keyomarsi K
    Cancer Res; 2010 Jun; 70(12):5085-95. PubMed ID: 20530684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G
    Chatterjee S; Huang EH; Christie I; Burns TF
    Mol Cancer Ther; 2017 Aug; 16(8):1658-1668. PubMed ID: 28566436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.
    Graves PR; Yu L; Schwarz JK; Gales J; Sausville EA; O'Connor PM; Piwnica-Worms H
    J Biol Chem; 2000 Feb; 275(8):5600-5. PubMed ID: 10681541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.
    Tsvetkov L; Stern DF
    Cell Cycle; 2005 Jan; 4(1):166-71. PubMed ID: 15611664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
    Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.
    Chen L; Ahmad N; Liu X
    Cell Cycle; 2016; 15(6):840-9. PubMed ID: 26900800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.